NASDAQ: ENLVEnlivex Therapeutics Ltd Stock
$1.76+0.05 (+2.92%)
Updated Dec 8, 2023
ENLV Price
$1.76
Fair Value Price
$2.34
Market Cap
$32.73M
52 Week Low
$1.27
52 Week High
$4.65
P/E
-1.2x
P/B
0.84x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$27.16M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.21
Operating Cash Flow
-$23M
Beta
0.57
Next Earnings
Dec 15, 2023
Ex-Dividend
N/A
Next Dividend
N/A
ENLV Overview
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ENLV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ENLV ($1.76) is undervalued by 24.67% relative to our estimate of its Fair Value price of $2.34 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ENLV ($1.76) is significantly undervalued by 24.67% relative to our estimate of its Fair Value price of $2.34 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ENLV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ENLV due diligence checks available for Premium users.
Be the first to know about important ENLV news, forecast changes, insider trades & much more!
ENLV News
Valuation
ENLV fair value
Fair Value of ENLV stock based on Discounted Cash Flow (DCF)
Price
$1.76
Fair Value
$2.34
Undervalued by
24.67%
ENLV ($1.76) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ENLV ($1.76) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ENLV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ENLV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.2x
Industry
11.7x
Market
31.32x
ENLV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.84x
Industry
5.42x
ENLV is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ENLV's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.0M
Profit Margin
0%
ENLV's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$46.9M
Liabilities
$8.2M
Debt to equity
0.21
ENLV's short-term assets ($31.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ENLV's short-term assets ($31.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ENLV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.4M
Investing
$3.9M
Financing
$0.0
ENLV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ENLV vs Biotech Stocks
Enlivex Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.